Toremifene Citrate Tablets (Ovry®) – 60?mg
$1.00
Toremifene citrate (brand name Ovry®), manufactured by Jiangsu Ascend Pharmaceutical Co., Ltd., is a selective estrogen receptor modulator (SERM) approved in China (NMPA No.?H20243050, code?86901425001187). Each box contains 30 tablets (60?mg each) in 3 blister cards (barcode?6953272600284). Strictly for laboratory research purposes only.
描述
Toremifene Citrate Product Specifications
| Attribute | Details |
|---|---|
| Product Name | Toremifene Citrate Tablets (Ovry®) |
| Strength | 60?mg per tablet |
| Quantity | 10 tablets per blister × 3 blisters = 30 tablets per box |
| Dosage Form | Oral tablet |
| Approval No. | China NMPA?H20243050 |
| Product Code | 86901425001187 |
| Barcode | 6953272600284 |
| Manufacturer | Jiangsu Ascend Pharmaceutical Co., Ltd. |
| Intended Use | Laboratory research use only — Not for human use |
Mechanism of Action
Toremifene is a SERM that functions as an estrogen receptor antagonist in breast tissue, while having partial estrogenic effects in bones and lipid metabolism. It is widely used as a reference compound in estrogen-receptor assays and breast cancer model systems.
Research & Reference Data
-
Clinically approved for metastatic estrogen-receptor–positive breast cancer in post-menopausal women, at a dose of 60?mg once daily.
-
Pharmacokinetics: nearly 100% oral bioavailability, half-life of 3–7 days, high protein binding (~99.7%). en.wikipedia.org
-
Known to prolong QT interval; commonly used in studies evaluating cardiac safety and receptor interactions. pubchem.ncbi.nlm.nih.gov+9dailymed.nlm.nih.gov+9dailymed.nlm.nih.gov+9
Research Applications
-
ER+ breast cancer cell models
-
Receptor binding and signaling assays
-
SERM comparative pharmacology
-
QT prolongation modeling and toxicity screening
?? Disclaimer
This product is provided strictly for laboratory research and development use only.
其他信息
| 重量 | 1.1 公斤 |
|---|---|
| 尺寸 | 18 × 16 × 18 厘米 |
Toremifene Citrate Tablets (Ovry®) – 60?mg 有 1 个评价
相关产品
-
Propranolol Hydrochloride Oral Solution 40?mg/5?mL Research & Analytical Use
Propranolol Hydrochloride Oral Solution (HeMeiJia) offers a sweet strawberry-mint 40?mg/5?mL formulation in a 40?mL bottle. Approved by NMPA under H20213549, this solution provides accurate dosing—ideal for infantile hemangioma, pediatric cardiovascular, or pharmacokinetic studies.
$1.00
?? For laboratory research or analytical purposes only – Not for therapeutic use. -
Abiraterone Acetate Tablets (Hengrui) – 250?mg × 120 Tablets per Bottle Price comparison
Abiraterone acetate is a potent CYP17A1 inhibitor used clinically to suppress androgen synthesis in prostate cancer. Manufactured by Chengdu Shengdi Pharmaceutical Co., Ltd., with China NMPA approval under H20193205 (product code: 86980435000069). This product is for laboratory research and development use only—not for clinical or therapeutic use. $2.00 -
Palbociclib Capsules (Xipeilai) – 125?mg, 21 Capsules Price comparison
Palbociclib Capsules (Research Grade) in 125?mg strength, 21-count bottle. Supplied by Shanghai Chuannuo Pharmaceutical Co., Ltd. For investigational or research applications only—not for human consumption or therapeutic use.
$2.00 -
Letrozole Capsules (Qipuyi®) – 2.5?mg?wholesale Price comparison
Letrozole is a potent nonsteroidal aromatase inhibitor, produced by Qilu Pharmaceutical Co., Ltd. (Qipuyi® brand). Each box contains 30 capsules (2.5?mg each), packaged as 3 blister cards. It’s approved in China under NMPA No.?H20213680, code 86981659000019, with barcodes 6915798005257 and 6915798005721. Strictly for laboratory research use—not for clinical or human applications. $1.00
mood –
The package is damaged, you need to resend it to me, thank you